Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.

Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, Rosenthal D.

J Clin Oncol. 2007 Aug 20;25(24):3635-43.

PMID:
17704413
2.

Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.

Sieswerda E, Kremer LC, Vidmar S, De Bruin ML, Smibert E, Sjöberg G, Cheung MM, Weintraub RG.

Pediatr Blood Cancer. 2010 Apr;54(4):579-84. doi: 10.1002/pbc.22371.

PMID:
20014238
3.

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer.

Dietz AC, Sivanandam S, Konety S, Kaufman CL, Gage RM, Kelly AS, Neglia JP, Mulrooney DA.

J Cancer Surviv. 2014 Jun;8(2):183-9. doi: 10.1007/s11764-013-0326-2. Epub 2013 Dec 7.

4.

Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines?

Pourier MS, Mavinkurve-Groothuis AM, Loonen J, Bökkerink JP, Roeleveld N, Beer G, Bellersen L, Kapusta L.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26243. Epub 2016 Sep 21.

PMID:
27654133
5.

Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.

Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, Pourier MS, Feuth T, Bökkerink JP, Hoogerbrugge PM, Kapusta L.

Pediatr Blood Cancer. 2009 May;52(5):631-6. doi: 10.1002/pbc.21913.

PMID:
19127569
6.

Cardiac complications in childhood cancer survivors treated with anthracyclines.

Franco VI, Lipshultz SE.

Cardiol Young. 2015 Aug;25 Suppl 2:107-16. doi: 10.1017/S1047951115000906. Review.

PMID:
26377717
7.

Cardiac function in Wilms' tumor survivors.

Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I.

J Clin Oncol. 1995 Jul;13(7):1546-56.

PMID:
7602343
8.

Subclinical late cardiac toxicity in childhood cancer survivors: impact on self-reported health.

Cox CL, Rai SN, Rosenthal D, Phipps S, Hudson MM.

Cancer. 2008 Apr 15;112(8):1835-44. doi: 10.1002/cncr.23378.

9.

Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Elbl L, Hrstkova H, Tomaskova I, Blazek B, Michalek J.

Eur J Pediatr. 2005 Nov;164(11):678-84. Epub 2005 Jul 26.

PMID:
16044276
10.

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B.

J Cancer Surviv. 2012 Mar;6(1):95-101. doi: 10.1007/s11764-011-0186-6. Epub 2011 Jun 1.

11.

Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines.

Pourier MS, Kapusta L, van Gennip A, Bökkerink JP, Loonen J, Bellersen L, Mavinkurve-Groothuis AM.

Clin Chim Acta. 2015 Feb 20;441:29-32. doi: 10.1016/j.cca.2014.12.011. Epub 2014 Dec 12.

PMID:
25512165
12.

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S.

Clin Cancer Res. 2014 Dec 15;20(24):6314-23. doi: 10.1158/1078-0432.CCR-13-3490. Epub 2014 Jun 19.

13.

Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.

Abosoudah I, Greenberg ML, Ness KK, Benson L, Nathan PC.

Pediatr Blood Cancer. 2011 Sep;57(3):467-72. doi: 10.1002/pbc.22989. Epub 2011 Jan 28.

PMID:
21280201
14.

Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?

Ramjaun A, AlDuhaiby E, Ahmed S, Wang L, Yu E, Nathan PC, Hodgson DC.

Pediatr Blood Cancer. 2015 Dec;62(12):2197-203. doi: 10.1002/pbc.25651. Epub 2015 Jul 6. Erratum in: Pediatr Blood Cancer. 2017 Mar;64(3):.

15.

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors.

Andolina JR, Dilley K.

J Pediatr Hematol Oncol. 2010 Jul;32(5):411-5. doi: 10.1097/MPH.0b013e3181dccd37.

PMID:
20495481
16.

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Cheuk DK, Sieswerda E, van Dalen EC, Postma A, Kremer LC.

Cochrane Database Syst Rev. 2016 Aug 23;(8):CD008011. doi: 10.1002/14651858.CD008011.pub3. Review.

PMID:
27552363
17.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ.

J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24.

18.

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?

Basar EZ, Corapcioglu F, Babaoglu K, Anik Y, Gorur Daglioz G, Dedeoglu R.

Pediatr Hematol Oncol. 2014 Apr;31(3):237-52. doi: 10.3109/08880018.2013.851753. Epub 2014 Feb 5.

PMID:
24499452
19.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
20.

Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.

Christiansen JR, Kanellopoulos A, Lund MB, Massey R, Dalen H, Kiserud CE, Ruud E, Aakhus S.

Pediatr Blood Cancer. 2015 Aug;62(8):1437-43. doi: 10.1002/pbc.25492. Epub 2015 Apr 1.

PMID:
25832752

Supplemental Content

Support Center